The combination of a ligand- and a structure-based drug design approach led to the identification of bis(hydroxyphenyl) azoles as potential inhibitors of 17beta-HSD1. Different azoles and hydroxy substitution patterns were investigated. The compounds were evaluated for activity and selectivity with regard to 17beta-HSD2, ERalpha and ERbeta. The most potent compound is 3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol
17beta-羟基类
固醇脱氢酶1(17beta-H
SD1)催化将活性较弱的
雌酮(E1)还原为最有效的
雌激素17beta-
雌二醇(E2)。E2通过激活
雌激素受体(ER)刺激激素依赖性疾病的生长。17beta-H
SD1通常在乳腺癌细胞中过表达。因此,它是治疗乳腺肿瘤的有吸引力的靶标。
配体和基于结构的药物设计方法的结合导致了对双(羟苯基)唑类化合物作为17β-H
SD1潜在
抑制剂的鉴定。研究了不同的唑和羟基取代方式。评估了化合物相对于17beta-H
SD2,ERalpha和ERbeta的活性和选择性。最有效的化合物是3- [5-(
4-羟基苯基)-1,3-
恶唑-2-基]
苯酚(18,IC(50)= 0.31 microM),